Viridian Therapeutics, Inc.\DE (VRDN) Profit After Tax (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Profit After Tax history runs 14 years deep, the most recent figure standing at -$105.9 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 22.21% year-over-year to -$105.9 million; the TTM figure through Mar 2026 stood at -$18.9 million (up 93.87% YoY), while the FY2025 annual figure was $457000.0, up 100.17% from the prior year.
• Profit After Tax for Q1 2026 stood at -$105.9 million, down from $222.3 million in the prior quarter.
• The five-year high for Profit After Tax was $222.3 million in Q4 2025, with the low at -$129.1 million in Q4 2022.
• The 5-year median for Profit After Tax is -$65.0 million (2024), against an average of -$46.9 million.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax soared 1422.22% in 2022, then tumbled 34808.76% in 2023.
• Viridian Therapeutics, Inc.\DE's Profit After Tax stood at -$129.1 million in 2022, then soared by 48.21% to -$66.9 million in 2023, then retreated by 20.13% to -$80.3 million in 2024, then surged by 376.81% to $222.3 million in 2025, then sank by 147.63% to -$105.9 million in 2026.
• Business Quant data shows VRDN's Profit After Tax at -$105.9 million in Q1 2026, $222.3 million in Q4 2025, and -$34.6 million in Q3 2025.